Project Grant HT9425261E319
Award Date 9/1/26
Completion Date 8/31/29
Dollars Obligated $3.5M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded MD Anderson Cancer Center a $1.4 million Project Grant on September 16, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support translational therapeutics research focused on accelerating the discovery and clinical application of cancer treatments, with particular emphasis on pancreatic cancer. The three-year award, extending through September 2029, funds basic and applied biomedical research...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded MD Anderson Cancer Center a $560K Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2026, through August 31, 2028. The award supports research on modulating hypoxia-activated stromal programs to potentiate chimeric antigen receptor T (CAR-T) cell therapy in kidney cancer. This project directly aligns with the DHA's mission to advance biomedical solutions for Service...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $5.47M Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025, through August 31, 2029. The award funds research aimed at targeting ganglioside GD2 to overcome chemotherapy resistance in triple-negative breast cancer. This research initiative represents translational and clinical investigation...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $817,496 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2028. The award funds research to investigate the PRMT3-IGF2BP1 axis-mediated epitranscriptomic reprogramming as a novel therapeutic strategy to overcome immunotherapy resistance in clear cell renal cell carcinoma...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $1.35 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the three-year period from October 1, 2025, through September 30, 2028. The award funds research focused on building T-cell products for neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumors (MPNST) through antigen discovery and...
- The University of Texas MD Anderson Cancer Center received a $1,354,543 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on August 1, 2025, with a completion date of July 31, 2028. The award supports a Phase 1 clinical trial evaluating engineered oncolytic Herpes Simplex Virus-1 (HSV-1) M032 as a therapeutic intervention for newly diagnosed diffuse midline glioma patients. This research contributes to the DHA's mission...
- This $3,945,543 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports cancer research and care initiatives at the University of Texas MD Anderson Cancer Center (MD Anderson). The award will fund a 4-year clinical research extension project to advance progress, precision, and equity in breast cancer care. MD Anderson, a leading comprehensive cancer center, will utilize the funding to conduct research activities that...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $893,525 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) beginning September 1, 2025, and concluding August 31, 2028. The award supports research targeting neuronal mimicry in SMARCB1-deficient renal medullary carcinoma treatment. This project advances precision oncology research addressing rare kidney cancer through investigation...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The University of Texas MD Anderson Cancer Center a $1.398 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) on June 1, 2026, for the three-year project "Combined PAN and Precision Targeting in Extrachromosomal DNA-Positive Gastric Cancer," with completion expected by May 31, 2029. This award supports investigator-initiated biomedical research addressing cancer therapeutics...
- The University of Texas MD Anderson Cancer Center received a $1.14M project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the three-year performance period from September 1, 2025 through August 31, 2028. The award supports research targeting the PRMT3-IGF2BP1 axis-mediated epitranscriptomic reprogramming as a novel therapeutic strategy to overcome immunotherapy resistance in clear cell renal cell carcinoma (CCRCC). The...